ZAI LAB LTD-ADR (ZLAB) Stock News

Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025

Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting

Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors

Earnings Scheduled For February 27, 2025

Mentions: SSP CLCO CVEO DCI ...

Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?

Mentions: NVCR

Hertz Global And Webull Stocks Are Among Top Mid-Cap Gainers Last Week (Apr 14-Apr 18): Are The Others In Your Portfolio?

Top mid-cap performers last week: Webull Corp, Hertz Global, Metsera Inc, Vista Energy, Certara Inc, Sibanye-Stillwater, Banco Macro, Grupo Financiero Galicia, Banco BBVA Argentina, Recursion Pharmaceuticals, Pampa Energia

Mentions: VIST BMA HTZ PFE ...

J&J projects $400m tariff hit but raises sales outlook

J&J is projecting a $400m hit due to US tariffs in 2025, but reaffirmed its profit outlook while raising its sales forecast.

Mentions: NVS JNJ BIDU CXDO ...

Zai Lab to Announce First Quarter 2025 Financial Results and Recent Corporate Updates on May 8, 2025

Why Summit Therapeutics Inc. (SMMT) Went Up On Thursday?

We recently published a list of 10 Firms Buck Thursday’s Market Bloodbath. In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other Thursday’s best performers. Investors sold off positions on Thursday, sending the stock market tumbling anew following President Donald Trump’s announcement that he had actually […]

Mentions: SMMT PFE WMT

Zai Lab Limited (ZLAB): Among Stocks Insiders Sold in April After Trump’s Tariff Rollout

We recently published a list of 10 Stocks Insiders Sold in April After Trump’s Tariff Rollout. In this article, we are going to take a look at where Zai Lab Limited (NASDAQ:ZLAB) stands against other stocks that insiders sold in April after Trump’s tariff rollout. Last week, President Donald Trump signed an executive order imposing […]

Mentions: JPM TSLA

Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting

Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer

Zai Lab Announces Participation in Investor Conferences in March 2025

NovoCure Q4 EPS Misses, Revenue Matches

NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges.

Mentions: NVCR MRK

Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates

Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025

Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)

Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia

Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer

Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore

Mentions: VRTX

Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore

Mentions: VRTX

Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate

Zai Lab Announces Participation in Investor Conference in January 2025

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Mentions: NVCR

Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List

Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)

Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares

Zai Lab Announces Pricing of Public Offering of American Depositary Shares

Zai Lab Announces Proposed Public Offering of American Depositary Shares

Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates